Brain scans track Alzheimer's clues over decades

NCT ID NCT00950430

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study uses special brain scans (PET imaging) to measure amyloid buildup—a protein linked to Alzheimer's—in healthy older adults, people with mild memory problems, and those with dementia. Participants receive scans every 2-3 years for up to 20 years to see how amyloid changes over time and relates to memory decline. The goal is to improve early diagnosis and understanding of Alzheimer's and related dementias.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Pittsburgh Compound B (C-11 PiB) and F-18 FDG
What this could lead to
If successful, this could lead to better early detection and tracking of Alzheimer's and other dementias, helping doctors diagnose and monitor these diseases more accurately.
What could go wrong
This is an observational imaging study, not a treatment trial. It may not directly improve patient outcomes, and results may take many years to yield practical benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.